TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30350761

Group type: COMPARATOR
Intervention: Interactive 24-h recall (i-24-HR)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Weighed food records
Number of subjects: 132
Study: 26314086

Group type: EXPERIMENTAL
Intervention: DAIRYCHOC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SOYCHOC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HEMPCHOC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MILK
Number of subjects: 8

Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 8
Study: 22933811

Group type: EXPERIMENTAL
Intervention: Distributed audiovisual attention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Focused visual attention
Number of subjects: 0
Study: 20529984

Group type: EXPERIMENTAL
Intervention: Small-dose nefopam (50 ng/mL)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Large-dose nefopam (100 ng/mL)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 7
Study: 18824706

Group type: EXPERIMENTAL
Intervention: IROX (irinotecan 200 mg/m² plus oxaliplatin 85 mg/m²)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Irinotecan alone (350 mg/m²)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: IROX
Number of subjects: 628

Group type: COMPARATOR
Intervention: Irinotecan alone
Number of subjects: 628
Study: 15619410

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 13
Study: 12162939

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 0
Study: 9459088

Group type: EXPERIMENTAL
Intervention: Purified FSH preparation (9 patients, 35 follicular fluid samples)
Number of subjects: 18

Group type: COMPARATOR
Intervention: FSH-dominant human menopausal gonadotropin (hMG) preparation (9 patients, 34 samples)
Number of subjects: 18
Study: 8182402

Group type: EXPERIMENTAL
Intervention: Anticoagulant (AC) therapy with intravenous heparin infusion for at least 6 days and oral AC therapy for 3 months
Number of subjects: 87

Group type: COMPARATOR
Intervention: No anticoagulant (non-AC) therapy
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Anticoagulant (AC) therapy
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both AC and non-AC groups
Number of subjects: 87
Study: 3234438

Group type: EXPERIMENTAL
Intervention: Low fat/high malto‐dextrin formula (2.6 g fat/100 ml, 8.1 g carbohydrate/100 ml, 2.8 g malto‐dextrin/100 ml)
Number of subjects: 11

Group type: COMPARATOR
Intervention: High fat/low malto‐dextrin formula (3.6 g fat/100 ml, 7.3 g carbohydrate/100 ml, 1.9 g malto‐dextrin/100 ml)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low fat formula
Number of subjects: 11
Study: 29153485

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300U/mL (Gla‐300) at 0.4U/kg/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300U/mL (Gla‐300) at 0.6U/kg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Insulin degludec 100U/mL (Deg‐100) at 0.4U/kg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Insulin degludec 100U/mL (Deg‐100) at 0.6U/kg/day
Number of subjects: 48
Study: 28211600

Group type: EXPERIMENTAL
Intervention: Individually tailored, pragmatically delivered progressive interventions
Number of subjects: 41

Group type: COMPARATOR
Intervention: Prescriptive sham to minimally progressive interventions
Number of subjects: 41
Study: 24792229

Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 22676626

Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal conjugate vaccine
Number of subjects: 12194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12194
Study: 20096138

Group type: EXPERIMENTAL
Intervention: Citalopram (20 to 40 mg) plus B12 (0.5 mg), B6 (25 mg) and folic acid (2 mg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Citalopram (20 to 40 mg) plus placebo
Number of subjects: 300
Study: 19008063

Group type: EXPERIMENTAL
Intervention: Dual flow injection protocol with saline chaser containing 20% contrast media
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard procedure for contrast-enhanced imaging of coronary arteries
Number of subjects: 106
Study: 16607927

Group type: EXPERIMENTAL
Intervention: QUICKI
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: FGIR
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: FIRI
Number of subjects: 171

Group type: COMPARATOR
Intervention: Fasting and 2-hour insulin levels
Number of subjects: 171
Study: 12580984

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg day(-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atenolol 50 mg day(-1)
Number of subjects: 12
Study: 8825162

Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH+) through partial zona dissection (PZD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No assisted hatching (AH‐)
Number of subjects: 120
Study: 7682266

Group type: EXPERIMENTAL
Intervention: Aprotinin 20,000 U/kg after induction, 20,000 U/kg added to the prime, and 20,000 U/kg every hour during cardiopulmonary bypass (low-dose regimen)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Aprotinin 35,000 U/kg after induction followed by an infusion of 10,000 U/kg.min until the end of the operation and 35,000 U/kg added to the prime (high-dose regimen)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No aprotinin used (control)
Number of subjects: 42

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group 1 (low-dose aprotinin)
Number of subjects: 42
Study: 3514480

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study: 29574443

Group type: EXPERIMENTAL
Intervention: Early CR (2 weeks post-surgery)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care CR (6 weeks post-surgery)
Number of subjects: 140
Study: 27893864

Group type: EXPERIMENTAL
Intervention: One4All intervention (rapid point‐of‐care HIV screening, CD4 and viral load testing with same‐day results and linkage to counselling)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: One4All intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 12
Study: 24606088

Group type: EXPERIMENTAL
Intervention: Weekly iv methylprednisolone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Daily iv methylprednisolone
Number of subjects: 80
Study: 21868186

Group type: EXPERIMENTAL
Intervention: In-person aftercare
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief telephone aftercare
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-active aftercare
Number of subjects: 0
Study: 20683501

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (25-150 mg equivalents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (25-100 mg equivalents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18778865

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-45mg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Metformin (1000-2000mg/day)
Number of subjects: 44
Study: 15754408

Group type: EXPERIMENTAL
Intervention: Surgical resection with postoperative chemotherapy
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 179
Study: 12066723

Group type: EXPERIMENTAL
Intervention: GIK group (500 ml of 50% dextrose solution containing 100 IU insulin and potassium 80 mmol infused at 0.75 ml kg(‐1) h(‐1))
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-GIK group (5% dextrose solution infused at the same rate)
Number of subjects: 42
Study: 10522560

Group type: EXPERIMENTAL
Intervention: Hyperuricemia
Number of subjects: 418
Study: 8808179

Group type: EXPERIMENTAL
Intervention: Mefloquine alone (750 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Mefloquine in combination with artemether (300 mg, given 24 hours prior)
Number of subjects: 27
Study: 1791605

Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 4736
Study: 393728

Group type: EXPERIMENTAL
Intervention: Spiramycin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 31062903

Group type: EXPERIMENTAL
Intervention: 6-month home-based behaviour change intervention incorporating goal setting, self-monitoring and feedback, with motivational interviewing (n = 201)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Waitlisted control group (n = 200)
Number of subjects: 401
Study: 27995521

Group type: EXPERIMENTAL
Intervention: Calcipotriol plus Betamethasone Dipropionate Aerosol Foam
Number of subjects: 35

Group type: COMPARATOR
Intervention: Betamethasone 17-Valerate-Medicated Plaster
Number of subjects: 35
Study: 26055848

Group type: EXPERIMENTAL
Intervention: Intervention group (attended two 6-session, 12-week group education modules)
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 698

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 698
Study: 23295710

Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification (ABM)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 102
Study: 21437436

Group type: EXPERIMENTAL
Intervention: Proximal row carpectomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Four-corner fusion
Number of subjects: 20
Study: 18788990

Group type: EXPERIMENTAL
Intervention: Isoflavones (70 mg) for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16785776

Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Exposure and response prevention (ERP)
Number of subjects: 10
Study: 14556830

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer
Number of subjects: 8

Group type: COMPARATOR
Intervention: Embryo transfer by clinical touch alone
Number of subjects: 8
Study: 10810399

Group type: EXPERIMENTAL
Intervention: UFT (400 mg daily) administered orally for seven days prior to surgery and MMC postoperatively (Group A)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: UFT (400 mg daily) administered orally for seven days prior to surgery and MMC postoperatively plus UFT orally at a dose of 400 mg daily for one year (Group B)
Number of subjects: 126
Study: 8857073

Group type: EXPERIMENTAL
Intervention: FK613 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FK613 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FK613 40 mg twice daily for 6.5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FK613 30 mg or more
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrogel-type formulation of FK613
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 0
Study: 1739560

Group type: EXPERIMENTAL
Intervention: 37% oxygen by face mask
Number of subjects: 35

Group type: COMPARATOR
Intervention: 21% oxygen by face mask
Number of subjects: 35
Study: 6712318

Group type: EXPERIMENTAL
Intervention: Pancreatic resection
Number of subjects: 35

Group type: COMPARATOR
Intervention: Peritoneal lavation
Number of subjects: 35
Study: 28691577

Group type: EXPERIMENTAL
Intervention: Five practice tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: One practice test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial length increase
Number of subjects: 0
Study: 26427984

Group type: EXPERIMENTAL
Intervention: vincristine-carboplatin
Number of subjects: 55

Group type: COMPARATOR
Intervention: etoposide-carboplatin
Number of subjects: 55
Study: 25637937

Group type: EXPERIMENTAL
Intervention: Olmesartan (n = 578)
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Control (n = 569)
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Olmesartan with ACE inhibitors and β-blockers
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Control with ACE inhibitors and β-blockers
Number of subjects: 1147
Study: 24119552

Group type: EXPERIMENTAL
Intervention: Education intervention group (education package encouraging reduction in sitting behaviors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sit-stand desk intervention group (education package + adjustable sit-stand desk)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 21843836

Group type: EXPERIMENTAL
Intervention: Resistance training (three sets of eight repetitions of quadriceps resistance exercise at 70% of one repetition maximum, supervised by physiotherapists)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard doses of oral corticosteroids and physiotherapy limited to airway clearance techniques and breathing exercises)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 40
Study: 17604664

Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg twice daily
Number of subjects: 528

Group type: COMPARATOR
Intervention: Fluticasone propionate 330 microg twice daily
Number of subjects: 528
Study: 17315803

Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 17% Ethylenediamintetraacetic acid (EDTA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prime&Bond NT + TPH resin-based composite
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prompt L-Pop + F2000
Number of subjects: 0
Study: 14743986

Group type: EXPERIMENTAL
Intervention: Warm-up and static stretch
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Static stretch only
Number of subjects: 56

Group type: COMPARATOR
Intervention: Warm-up only
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study: 10919732

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/day)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU d‐alpha‐tocopheryl acetate/day)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Combined vitamins C and E
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 8808724

Group type: EXPERIMENTAL
Intervention: 8 mg i.v. bolus of ondansetron
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 mg i.v. granisetron
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 mg i.v. tropisetron
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no further antiemetic therapy)
Number of subjects: 60
Study: 1318390

Group type: EXPERIMENTAL
Intervention: P/B (PAK and sodium bicarbonate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PAK (Pyridoxine-alpha-ketoglutarate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BIC (Sodium bicarbonate and placebo)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study: 3936091

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Diazepam (0.15 mg/kg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Diazepam (0.30 mg/kg)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Caffeine (0 mg/kg) + Diazepam (0.15 mg/kg)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Caffeine (0 mg/kg) + Diazepam (0.30 mg/kg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg) + Diazepam (0.15 mg/kg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg) + Diazepam (0.30 mg/kg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg) + Diazepam (0.15 mg/kg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg) + Diazepam (0.30 mg/kg)
Number of subjects: 108
Study: 31701891

Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion stimulation
Number of subjects: 93

Group type: COMPARATOR
Intervention: Sham control (cutaneous electrical stimulation)
Number of subjects: 93
Study: 28815560

Group type: EXPERIMENTAL
Intervention: Lindioil ointment containing 200 μg g‐1 of indirubin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lindioil ointment containing 100 μg g‐1 of indirubin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lindioil ointment containing 50 μg g‐1 of indirubin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lindioil ointment containing 10 μg g‐1 of indirubin
Number of subjects: 0
Study: 26693802

Group type: EXPERIMENTAL
Intervention: Vibration Training (VT) targeting lower limb muscles, frequency 30-50 Hz, three times per week until discharge, amplitude increased from 2 to 5 mm
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care physiotherapy sessions
Number of subjects: 56
Study: 24140226

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Antidepressants (MED)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combined CBT and antidepressants (COMB)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Standard treatment (ST)
Number of subjects: 180
Study: 22648221

Group type: EXPERIMENTAL
Intervention: Treatment A (novel anti-acne/anti-aging formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment B (tretinoin cream 0.025%)
Number of subjects: 0
Study: 19780041

Group type: EXPERIMENTAL
Intervention: Caloric air stimulation of the right ear
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 10
Study: 18666803

Group type: EXPERIMENTAL
Intervention: Irbesartan therapy for 9 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo therapy for 9 weeks
Number of subjects: 60
Study: 16613662

Group type: EXPERIMENTAL
Intervention: Gallium nitrate 200 mg/m2 daily for 5 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pamidronate 60 mg (increased to 90 mg for initial serum calcium > or = 13.5 mg/dL) followed by placebo infusions for 4 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pamidronate 90 mg for initial serum calcium > or = 13.5 mg/dL
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pamidronate 60 mg for initial serum calcium > or = 13.5 mg/dL
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Gallium nitrate for initial serum calcium > or = 13.5 mg/dL
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pamidronate
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Gallium nitrate
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pamidronate (responders)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Gallium nitrate (responders)
Number of subjects: 64
Study: 14616318

Group type: EXPERIMENTAL
Intervention: Mivacurium (0.1 mg kg‐1 bolus followed by continuous infusion)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison with phenotypically normal patients (UU)
Number of subjects: 32
Study: 11018164

Group type: EXPERIMENTAL
Intervention: long-long regimen (zidovudine starting at 28 weeks' gestation, 6 weeks treatment in infant)
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: long-short regimen (zidovudine starting at 28 weeks' gestation, 3 days treatment in infant)
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: short-long regimen (zidovudine starting at 35 weeks' gestation, 6 weeks treatment in infant)
Number of subjects: 1437

Group type: COMPARATOR
Intervention: short-short regimen (zidovudine starting at 35 weeks' gestation, 3 days treatment in infant)
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: in utero transmission (short regimens)
Number of subjects: 1437

Group type: EXPERIMENTAL
Intervention: in utero transmission (long regimens)
Number of subjects: 1437
Study: 8842912

Group type: EXPERIMENTAL
Intervention: Single syringe method
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Closed gravity drainage system
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Closed double syringe method
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (no lavage)
Number of subjects: 5
Study: 10148407

Group type: EXPERIMENTAL
Intervention: Rotorest Kinetic Treatment Table
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional hospital bed
Number of subjects: 100
Study: 6660456

Group type: EXPERIMENTAL
Intervention: Lateral position after bupivacaine administration
Number of subjects: 70

Group type: COMPARATOR
Intervention: Supine position after bupivacaine administration
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 70

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 70
Study: 31533841

Group type: EXPERIMENTAL
Intervention: Audit and feedback with action implementation toolbox
Number of subjects: 21

Group type: COMPARATOR
Intervention: Audit and feedback only (without toolbox)
Number of subjects: 21
Study: 29998882

Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (Peg-IFN) for 48 weeks
Number of subjects: 162

Group type: COMPARATOR
Intervention: Entecavir (ETV) for 12 weeks followed by Peg-IFN for 48 weeks (sequential treatment)
Number of subjects: 162
Study: 27154394

Group type: EXPERIMENTAL
Intervention: Enterovirus quantity at the time of OPV administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enterovirus quantity
Number of subjects: 0
Study: 25261378

Group type: EXPERIMENTAL
Intervention: Controlled Temperature Chain (CTC; up to 40 °C for <30 days)
Number of subjects: 2128

Group type: COMPARATOR
Intervention: Standard Cold Chain (SCC; 2‐8 °C)
Number of subjects: 2128
Study: 23167789

Group type: EXPERIMENTAL
Intervention: Midwall EF in LVH group (42.8±4.4%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Midwall FS in LVH group (13.4±2.8%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EF in LVH group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Midwall EF correlation with LVMI
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Midwall FS correlation with LVMI
Number of subjects: 60